EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx



Status:Approved for marketing
Conditions:Cancer, Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/17/2018

Use our guide to learn which trials are right for you!

Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Neuroendocrine Tumors, Progressive Under Somatostatin Analogue Therapy

Advanced Accelerator Applications is currently pursuing marketing approval for
177Lu-DOTA0-Tyr3-Octreotate (Lutathera). This expanded access therapeutic protocol aims to
allow patients suffering from inoperable, somatostatin receptor positive, neuroendocrine
tumors, progressive under somatostatin analogue therapy to access the investigational
product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to its commercial availability.

Advanced Accelerator Applications activated in 2012 a multicenter, stratified, open,
randomized, comparator-controlled, parallel-group Phase III study comparing treatment with
177Lu-DOTA0-Tyr3-Octreotate to 60 mg Octreotide LAR in patients with inoperable, progressive,
somatostatin receptor positive, midgut carcinoid tumors (NETTER-1 trial, EudraCT number
2011-005049-11, IND number 77219).

Clinical studies, including NETTER-1 for which the primary analysis has been conducted,
showed clinical evidence of safety and effectiveness to support the expanded access use
without any unreasonable potential risks for the patients in the context of the disease to be
treated.

In July 2016, the first patient was treated under an Expanded Access Program (EAP) for
inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumors.

Compassionate use programs in Europe include pulmonary NETs. In the US, there were many
centers with patients with NETs who did not meet the inclusion criteria for the original EAP.
In May 2017, Advanced Accelerator Applications inquired with the FDA if amending the
inclusion criteria of the original protocol to include all NETs would be permissible.

In June 2017, Advanced Accelerator Applications was able to submit a revision to the original
Expanded Access Program's protocol for 177Lu-DOTA0-Tyr3-Octreotate to include neuroendocrine
tumors arising from sites other than midgut.

The locations listed below that are participating in the EAP may have received IRB approval
for either the original protocol or the new protocol or both. Please, inquire with the
Facility Contact as to which protocol is active at their site.

Inclusion Criteria:

- Presence of metastasized or locally advanced neuroendocrine tumor, inoperable
(curative intent) at enrollment time, and regardless of the origin of the tumor.

- Ki67 index ≤ 20%

- Patients progressive under SSA (any dose) at the time of enrollment

- Target lesions over-expressing somatostatin receptors according to an appropriate
imaging method (e.g. 111In-pentetreotide (Octreoscan) imaging or
68Ga-DOTA0-Tyr3-Octreotate (or 68Ga-edotreotide) imaging)

Exclusion Criteria:

- Either serum creatinine >150 μmol/L (>1.7 mg/dL), or creatinine clearance <50 mL/min
calculated by the Cockroft Gault method, eventually confirmed by measured creatinine
clearance (or measured glomerular filtration rate (GFR) using plasma clearance
methods, not gamma camera-based) <50 mL/min (the measured creatinine clearance / GFR
is required only as confirmatory exam).

- Hb concentration <5.0 mmol/L (<8.0 g/dL); WBC <2x109/L (2000/mm3); platelets <75x109/L
(75x103/mm3).

- Total bilirubin >3 x ULN.

- Serum albumin <3.0 g/dL unless prothrombin time is within the normal range.

- Pregnancy or lactation.

- For female patients of childbearing potential (defined as < 2 years after last
menstruation and not surgically sterile) and male patients, who are not surgically
sterile or with female partners of childbearing potential: absence of effective,
non-hormonal means of contraception (intrauterine contraceptive device, barrier method
of contraception in conjunction with spermicidal gel).

- Any surgery, radioembolization, chemoembolization, chemotherapy and radiofrequency
ablation within 12 weeks prior to enrollment.

- Interferons, Everolimus (mTOR-inhibitors) or other systemic therapies within 4 weeks
prior to enrollment.

- Known brain metastases, unless these metastases have been treated and stabilized.

- Uncontrolled congestive heart failure (NYHA II, III, IV).

- Uncontrolled diabetes mellitus as defined by a fasting blood glucose >2 ULN.

- Any patient receiving treatment with short-acting Octreotide, which cannot be
interrupted for 24 h before and 24 h after the administration of
177Lu-DOTA0-Tyr3-Octreotate, or any patient receiving treatment with Octreotide LAR,
which cannot be interrupted for at least 4 weeks before the administration of
177Lu-DOTA0-Tyr3-Octreotate, unless the tumor uptake on target lesions is at least as
high as normal liver uptake.

- Patients with any other significant medical, psychiatric, or surgical condition,
currently uncontrolled by treatment, which may pose a risk to the patient safety

- Prior external beam radiation therapy to more than 25% of the bone marrow.

- Current spontaneous urinary incontinence making impossible the safe administration of
the radioactive IMP.

- Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in
situ of the uterine cervix, unless definitively treated and with no evidence of
recurrence.

- Patients who have not provided a signed informed consent form to accept this
treatment.
We found this trial at
41
sites
Philadelphia, Pennsylvania 19111
Principal Investigator: Namrata Vijayvergia, MD
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
4201 Belfort Road
Jacksonville, Florida 32216
(408) 293-2336
Principal Investigator: Pashtoon Kasi, MD
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1364 Clifton Rd NE
Atlanta, Georgia 30322
(404) 712-2000
Emory University Hospital As the largest health care system in Georgia and the only health...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Baltimore, Maryland 21287
Principal Investigator: Lilja Solnes, MD, MBA
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Chicago, Illinois 60611
Principal Investigator: Al B Benson III, MD
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Allan V. Espinosa Morazan, MD
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Andrew S Paulson, MD
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
Principal Investigator: Rathan Subramaniam, MD, PhD, MPH
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80218
?
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Durham, North Carolina 27705
?
mi
from
Durham, NC
Click here to add this to my saved trials
Gilbert, Arizona 85234
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
104 Innovation Drive
Greenville, South Carolina 29697
?
mi
from
Greenville, SC
Click here to add this to my saved trials
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
425 Volker Boulevard
Kansas City, Missouri 64131
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Kenner, Louisiana
?
mi
from
Kenner, LA
Click here to add this to my saved trials
1428 Madison Ave
New York, New York 10029
(212) 241-6500
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Newnan, GA
Click here to add this to my saved trials
17201 Wright Street
Omaha, Nebraska 68130
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Phoenix, Arizona
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Roanoke, Virginia
?
mi
from
Roanoke, VA
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
700 Lawrence Expressway
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Seattle, Washington 98101
(888) 862-2737
Principal Investigator: Hagen F Kennecke, MD
Virginia Mason Medical Center Established in 1920, Virginia Mason began as an 80-bed hospital with...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Seattle, Washington 98185
Principal Investigator: Manuela Matesan, M.D., Ph.D.
?
mi
from
Seattle, WA
Click here to add this to my saved trials
300 Pasteur Dr
Stanford, California 94305
(650) 723-4000
Stanford Univ Med Ctr The Medical Center is uniquely advantaged by its location on the...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
3 Edmund D. Pellegrino Road
Stony Brook, New York 11794
Principal Investigator: Dinko Franceschi, MD
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Tampa, Florida 33612
?
mi
from
Tampa, FL
Click here to add this to my saved trials